Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Feugier

Showing results (121-130 of 164) with videos related to

Pageof 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2015
The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study AssociationRobert Kridel, Luc Xerri, Bénédicte Gelas-Dore, et al.
Blood Advances|November 12, 2020
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphomaLaetitia Vercellino, Roberta Di Blasi, Salim Kanoun, et al.
Ejhaem|August 13, 2025
A Pilot Collaborative Study to Improve the Diagnosis and Treatment of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma in Senegal: The LYMPHODAK StudySaliou Diop, Charline Moulin, Sokhna Aïssatou Touré, et al.
Haematologica|May 28, 2026
Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa studyJulien Lazarovici, Sandy Amorim, Krimo Bouabdallah, et al.
Nature Communications|August 9, 2024
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trialRomain Guièze, Loïc Ysebaert, Damien Roos-Weil, et al.
Blood|January 25, 2020
High total metabolic tumor volume at baseline predicts survival independent of response to therapyLaetitia Vercellino, Anne-Segolene Cottereau, Olivier Casasnovas, et al.
Blood Advances|January 9, 2026
Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphomaEmilie Charton, Amélie Anota, Emmannuel Bachy, et al.
Nature Medicine|October 9, 2023
Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trialRoch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
Lancet (London, England)|December 24, 2010
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trialGilles Salles, John Francis Seymour, Fritz Offner, et al.
The New England Journal of Medicine|September 28, 2017
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell LymphomaSteven Le Gouill, Catherine Thieblemont, Lucie Oberic, et al.
Pageof 17

Showing results (121-130 of 164) with videos related to

Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2015
The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study AssociationRobert Kridel, Luc Xerri, Bénédicte Gelas-Dore, et al.
Blood Advances|November 12, 2020
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphomaLaetitia Vercellino, Roberta Di Blasi, Salim Kanoun, et al.
Ejhaem|August 13, 2025
A Pilot Collaborative Study to Improve the Diagnosis and Treatment of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma in Senegal: The LYMPHODAK StudySaliou Diop, Charline Moulin, Sokhna Aïssatou Touré, et al.
Haematologica|May 28, 2026
Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa studyJulien Lazarovici, Sandy Amorim, Krimo Bouabdallah, et al.
Nature Communications|August 9, 2024
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trialRomain Guièze, Loïc Ysebaert, Damien Roos-Weil, et al.
Blood|January 25, 2020
High total metabolic tumor volume at baseline predicts survival independent of response to therapyLaetitia Vercellino, Anne-Segolene Cottereau, Olivier Casasnovas, et al.
Blood Advances|January 9, 2026
Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphomaEmilie Charton, Amélie Anota, Emmannuel Bachy, et al.
Nature Medicine|October 9, 2023
Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trialRoch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
Lancet (London, England)|December 24, 2010
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trialGilles Salles, John Francis Seymour, Fritz Offner, et al.
The New England Journal of Medicine|September 28, 2017
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell LymphomaSteven Le Gouill, Catherine Thieblemont, Lucie Oberic, et al.
Pageof 17